Form 4: Director Daniel J. Sajkowski Sells Calumet Shares

Director Daniel J. Sajkowski sold 3,310 shares of Calumet, Inc. common stock on April 1, 2026, via a Rule 10b5-1 trading plan.

Summary

• Director Daniel J. Sajkowski disposed of 3,310 shares of Calumet, Inc. (CLMT) common stock.
• The shares were sold at a weighted average price of $34.46 per share.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2025.
• Following the transaction, the reporting person retains beneficial ownership of 81,958 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a small portion of the director's total holdings.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell stock without concerns regarding non-public information.

Negatives

• The transaction represents a reduction in the director's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived by the market as a signal that the stock price has reached a near-term peak.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person has committed to providing full details regarding the number of shares sold at each specific price point within the reported range upon request.

Industry Context

StockSavvy.ai notes that insider sales executed via 10b5-1 plans are routine corporate governance events and generally do not reflect a change in management's outlook on the company's fundamental business performance.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan is the industry standard for corporate insiders to manage personal liquidity while maintaining compliance with SEC regulations.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was executed through a pre-planned trading arrangement.

Next Steps

• No further actions or milestones were disclosed in this filing.

Key Dates

Keywords

Calumet, CLMT, Insider Trading, Form 4, Director Sale, Rule 10b5-1